Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 4/2010

01-12-2010

Depression After Myocardial Infarction

Authors: Melvin R. Echols, Christopher M. O’Connor

Published in: Current Heart Failure Reports | Issue 4/2010

Login to get access

Abstract

Depression is an important disease state that requires significant time and resources to manage properly. The presence of depression in patients with cardiovascular disease has been strongly associated with detrimental effects in terms of morbidity and mortality. Although several large-scale and small studies have evaluated various interventions in the management of depression after myocardial infarction, a significant portion of these data have provided more questions than answers. Although limited, the randomized prospective clinical trial data evaluating interventions for the management of depression after myocardial infarction in patients with ischemic heart disease continue to produce promising findings for progressive and improved management of these devastating diseases.
Literature
1.
Jiang W, Babyak MA, Rozanski A, et al.: Depression and increased myocardial ischemic activity in patients with ischemic heart disease. Am Heart J 2003, 146:55–61.CrossRefPubMed
2.
Jiang W, Krishnan RR, O’Connor CM: Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002, 16:111–127.CrossRefPubMed
3.
Carney RM, Freedland KE, Jaffe AS, et al.: Depression as a risk factor for post-MI mortality. J Am Coll Cardiol 2004, 44:472.CrossRefPubMed
4.
O’Connor CM, Jiang W, Kuchibhatla M, et al.: Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008, 168:2232–2237.CrossRefPubMed
5.
Pozuelo L, Tesar G, Zhang J, et al.: Depression and heart disease: what do we know, and where are we headed? Cleve Clin J Med 2009, 76:59–70.CrossRefPubMed
6.
Davidson KW, Burg MM, Kronish IM, et al.: Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch Gen Psychiatry 2010, 67:480–488.CrossRefPubMed
7.
O’Connor CM, Glassman AH, Harrison DJ: Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J Clin Psychiatry 2005, 66:346–352.CrossRefPubMed
8.
Jiang W: Impacts of depression and emotional distress on cardiac disease. Cleve Clin J Med 2008, 75(Suppl 2):S20–S25.CrossRefPubMed
9.
Barefoot JC, Helms MJ, Mark DB, et al.: Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996, 78:613–617.CrossRefPubMed
10.
Bush DE, Ziegelstein RC, Tayback M, et al.: Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001, 88:337–341.CrossRefPubMed
11.
Jiang W, Krishnan RR: Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? Curr Psychiatry Rep 2004, 6:202–209.CrossRefPubMed
12.
• Lespérance F, Frasure-Smith N, Koszycki D, et al.: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007, 297:367–379. (Published erratum appears in JAMA 2007, 298:40.) The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy was a randomized, controlled, 12-week, parallel-group, 2 × 2 factorial trial among 284 patients with coronary artery disease from nine Canadian academic centers. There was no evidence of a benefit of interpersonal psychotherapy over clinical management, with the mean HAM-D difference favoring clinical management (–2.26 points; 96.7% CI, –4.78 to 0.27; P = 0.06; effect size, 0.23).
13.
Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 1998, 155:4–11.PubMed
14.
Barefoot JC, Schroll M: Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996, 93:1976–1980.PubMed
15.
Frasure-Smith N, Lespérance F, Gravel G, et al.: Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res 2000, 48:471–478.CrossRefPubMed
16.
O’Connor CM, Joynt KE: Depression: are we ignoring an important comorbidity in heart failure? J Am Coll Cardiol 2004, 43:1550–1552.CrossRefPubMed
17.
O’Connor EA, Whitlock EP, Beil TL, Gaynes BN: Screening for depression in adult patients in primary care settings: a systematic evidence review. Ann Intern Med 2009, 151:793–803.PubMed
18.
Jiang W, Glassman A, Krishnan R, et al.: Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J 2005, 150:54–78.CrossRefPubMed
19.
Frasure-Smith N, Lespérance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. Circulation 1995, 91:999–1005. (Published erratum appears in Circulation 1998, 97:708.)
20.
Lespérance F, Frasure-Smith N, Juneau M, Théroux P: Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000, 160:1354–1360.CrossRefPubMed
21.
Frasure-Smith N, Lespérance F, Gravel G, et al.: Long-term survival differences among low-anxious, high-anxious and repressive copers enrolled in the Montreal heart attack readjustment trial. Psychosom Med 2002, 64:571–579.CrossRefPubMed
22.
Jiang W, Davidson JR: Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005, 150:871–881.CrossRefPubMed
23.
Bigger JT Jr, Fleiss JL, Kleiger R, et al.: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984, 69:250–258.PubMed
24.
Greenberg HM, Dwyer EM Jr, Hochman JS, et al.: Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995, 74:631–635.CrossRefPubMed
25.
Glassman AH, Roose SP, Bigger JT Jr: The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993, 269:2673–2675.
26.
Roose SP, Glassman AH, Giardina EG, et al.: Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987, 7:247–251.CrossRefPubMed
27.
Roose SP, Glassman AH, Giardina EG, et al.: Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986, 256:3253–3257.CrossRefPubMed
28.
Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.CrossRefPubMed
29.
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992, 327:227–233.CrossRef
30.
Shapiro PA: Treatment of depression in patients with congestive heart failure. Heart Fail Rev 2009, 14:7–12.CrossRefPubMed
31.
Jiang W, Blumenthal JA: Depression and ischemic heart disease: overview of the evidence and treatment implications. Curr Psychiatry Rep 2003, 5:47–54.CrossRefPubMed
32.
Watson K, Summers KM: Depression in patients with heart failure: clinical implications and management. Pharmacotherapy 2009, 29:49–63.CrossRefPubMed
33.
Roose SP, Glassman AH, Attia E, et al.: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998, 155:660–665.PubMed
34.
Rutledge T, Reis VA, Linke SE, et al.: Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006, 48:1527–1537.CrossRefPubMed
35.
Frasure-Smith N, Lespérance F, Prince RH, et al.: Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet 1997, 350:473–479.CrossRefPubMed
36.
Kellner R, Uhlenhuth EH: The rating and self-rating of anxiety. Br J Psychiatry Suppl 1991, (12):15–22.PubMed
37.
Berkman LF, Blumenthal J, Burg M, et al.: Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003, 289:3106–3116.CrossRefPubMed
38.
Glassman AH, O’Connor CM, Califf RM, et al.: Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288:701–709. (Published erratum appears in JAMA 2002, 288:1720.)
39.
Serebruany VL, Glassman AH, Malinin AI, et al.: Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003, 108:939–944. (Published erratum appears in Circulation 2003, 108:3165.)
40.
Kotzailias N, Andonovski T, Dukic A, et al.: Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial. J Clin Pharmacol 2006, 46:468–475.CrossRefPubMed
41.
•• Hansen BH, Hanash JA, Rasmussen A, et al.: Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). Trials 2009, 10:20. The Depression in Acute Coronary Syndrome (DECARD) trial has been initiated to evaluate the use of the SSRI escitalopram in the possible prevention of depression in patients after ACS. The investigators of the published trial design seek to randomize 240 patients with ACS without depression to receive either escitalopram or placebo for 1 year to assess the rates of depression with preempted use of antidepressant therapy. The trial is still ongoing.PubMed
42.
•• Roncella A, Giornetti A, Cianfrocca C, et al.: Rationale and trial design of a randomized, controlled study on short-term psychotherapy after acute myocardial infarction: the STEP-IN-AMI trial (Short Term Psychotherapy in Acute Myocardial Infarction). J Cardiovasc Med (Hagerstown) 2009, 10:947–452. Short Term Psychotherapy in Acute Myocardial Infarction (STEP-IN-AMI) will assess the use of short-term cognitive behavioral therapy on clinical outcomes of patients who have undergone emergent PCI in the setting of acute MI. This study will provide insight into the use of short-term psychotherapy and how this intervention possibly affects clinical outcomes after interventional and medical treatment of AMI.CrossRef
43.
Jiang W, Alexander J, Christopher E, et al.: Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001, 161:1849–1856.CrossRefPubMed
44.
Jiang W, Kuchibhatla M, Clary GL, et al.: Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007, 154:102–108.CrossRefPubMed
45.
Jiang W, Hasselblad V, Krishnan RR, O’Connor CM: Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression. J Am Coll Cardiol 2002, 39:919–921.CrossRefPubMed
46.
•• Jiang W, O'Connor C, Silva SG, et al.: Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J 2008, 156:437–444. The Safety and Efficacy of Sertraline for Depression in Patients with Chronic Heart Failure (SADHART-CHF) is a prospective, randomized, double-blind, placebo-controlled trial that randomized a total of 469 heart failure patients with MDD to either sertraline (n = 234) or placebo (n = 235). At the end of the 12-week treatment, there were no significant differences in depression between patients receiving either sertraline or placebo. Even so, both groups had significant improvement in depression independently.CrossRefPubMed
47.
Mehra MR, Rockman HA, Greenberg BH: Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. Toronto, Ontario, Canada, September 20–23, 2008. J Am Coll Cardiol 2009, 53:514–522.CrossRefPubMed
48.
•• Angermann CE, Gelbrich G, Stork S, et al.: Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007, 9:1212–1222. The Morbidity, Mortality and Mood in Depressed Heart Failure (MOOD-HF) study is an ongoing prospective, randomized, double-blind, multicenter trial investigating the efforts of the SSRI escitalopram on morbidity and mortality, severity of depression, anxiety, cognitive function, and quality of life in an estimated 700 patients. The primary end point for this analysis is time to first event of either death or unplanned hospitalization. The results of the primary analysis of MOOD-HF and subset studies hopefully will provide valuable confirmation for aggressive management of depression treatment in patients with heart failure.CrossRefPubMed
49.
Kennedy SH, Andersen HF, Thase ME: Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009, 25:161–175.CrossRefPubMed
Metadata
Title
Depression After Myocardial Infarction
Authors
Melvin R. Echols
Christopher M. O’Connor
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 4/2010
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-010-0024-6

Other articles of this Issue 4/2010

Current Heart Failure Reports 4/2010 Go to the issue

ReviewPaper

Erectile Dysfunction as a Complication of Heart Failure

ReviewPaper

Cardiac Assessment in Duchenne and Becker Muscular Dystrophies

ReviewPaper

Right Ventricular Failure: A Novel Era of Targeted Therapy

ReviewPaper

Mechanical Circulatory Support as a Bridge to Transplant or for Destination Therapy

ReviewPaper

Sleep Apnea in Congestive Heart Failure

Invited Commentary

Familial Occurrence of Peripartum Cardiomyopathy Presages a Genetic Rather Than an Environmental Cause
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits